Evidence, Not Claims. Credibility You Can Verify.
The supplement industry runs on promises. Mere runs on clinical infrastructure, practitioner validation, and measurable outcomes. This is the evidence stack behind that claim.
Five Layers of Validation
Each layer reinforces the others. AI concordance proves the technology works. Manufacturing scale proves it ships. Adherence data proves patients stay. Clinical infrastructure proves the protocols are real. The patent proves the formulation is protected.
0%
AI Concordance
NORA AI matched expert TCM practitioner diagnosis in an N=200 clinical pilot. Dual encoders (ViT + 1D-CNN/LSTM) with adaptive attention fusion deliver organ-function trend indices in under 5 seconds.
0.0M
Prescriptions Fulfilled
Okchundang has fulfilled over 3.1 million prescriptions since 2014 across four hGMP production lines. This is not a theoretical supply chain. It is a decade of proven manufacturing at scale.
0%
Early Cohort Adherence
Early cohort data shows 90% adherence, roughly 3x the industry average of 30%. Practitioner-referred patients stay because the protocol is personalized and the source is trusted.
0 yrs
VUIM Clinical Infrastructure
Two decades of clinical training, patient data, and practitioner networks. This is the institutional foundation that turns Mere from a supplement brand into a clinical platform.
KR 10-1771125
Korean Patent Granted
Korean Patent KR 10-1771125 covers the cyclodextrin capture process that preserves volatile aromatic compounds conventional high-heat extraction destroys. Composition-of-matter protection with a 15-year R&D moat.
Why Clinical Credibility Matters
The supplement industry has a credibility problem. Consumers are skeptical, and they should be. Most brands offer no clinical evidence, no practitioner oversight, and no feedback mechanism. Mere's practitioner-first model and clinical validation infrastructure solve this trust deficit at the structural level.
50%
of consumers trust that supplements actually work
65%
feel more confident filing taxes than choosing supplements
15%
increase in perceived value when supplements have clinical trials
The Practitioner-First Advantage
When a trusted clinician recommends a protocol, adherence jumps from 30% to 90%. When that protocol adapts every 30 days based on measured response, retention compounds. Supplements backed by clinical trials increase perceived value by up to 15%. Mere is not asking consumers to trust a brand. It is asking them to trust their practitioner, who trusts the evidence.
Dr. Lixing Lao
VP of Clinical Research
President and Professor at Virginia University of Integrative Medicine. Globally recognized leader in acupuncture and integrative medicine research. His involvement strengthens practitioner adoption and de-risks regulatory diligence for investors evaluating clinical credibility.
Dr. Lao defines the validation protocols, practitioner-acceptable outcomes, and clinical guardrails that separate Mere from supplement brands making unsubstantiated claims. His research portfolio and institutional authority give practitioners the confidence to prescribe and investors the confidence to fund.
0+
Published Works
0+
Citations
Compliant by Design, Not by Reaction
Mere is structured to operate cleanly within existing regulatory frameworks. No medical claims. No diagnostic positioning. Structure/function only, with automated safety checks and clinician oversight baked into the platform.
NanoActives under DSHEA
Structured as dietary supplements with structure/function claims only. No claims to diagnose, treat, cure, or prevent disease. All formulations follow hGMP manufacturing standards with lot-level COA traceability.
Pulse as General Wellness Device
Positioned as a general wellness device, non-diagnostic. Captures biometric data for trend analysis and protocol personalization. Not a medical device.
Automated Herb-Drug Interaction Checks
Built into the platform layer. Automated screening flags potential interactions before formulations are dispensed. Clinician review for edge cases provides an additional safety layer.
No Medical Claims
Mere makes no diagnostic or therapeutic claims. Structure/function positioning protects against regulatory exposure while clinical data builds credibility with practitioners who need evidence.
IRB Replication Study
Planned Q2 2026The 92% concordance finding from the N=200 pilot is strong. But Mere is not waiting for regulators to ask for more evidence. The IRB replication study is planned for Q2 2026 to validate that result under institutional review, with independent oversight and standardized methodology.
This is proactive validation, not reactive compliance. The study will strengthen the evidence base for practitioner adoption, investor diligence, and any future regulatory conversations. It also generates the structured clinical data that feeds back into NORA AI model improvement.
Replicate 92% concordance under institutional review
Independent oversight with standardized methodology
Generate structured data for NORA AI model refinement
Strengthen evidence base for practitioner adoption